A carregar...
Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines
Doxorubicin plays an integral role in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) but can be associated with significant toxicity. Treatment guidelines of British Columbia (BC) Cancer recommend the substitution of etoposide for doxorubicin in standard-dose R-CHOP (rituximab,...
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7948286/ https://ncbi.nlm.nih.gov/pubmed/33683338 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002982 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|